The FDA on Wednesday approved the first-ever glucose monitoring system specifically for weight loss from the startup Signos, establishing a new option for Americans to manage their weight. The Signos system offers three- and six-month plans ($139 and $129 a month, respectively, and the company will send all of the continuous glucose monitors a patient needs.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
